Remedor Biomed develops medications for skin wounds that do not respond well to current treatment options.

The company's technology platform is based on a formulation containing a naturally occurring glycoprotein, erythropoietin, which is active in each phase of the healing process.The company's technology is protected by two patents related to wound healing, bone regeneration, and cosmetic applications.

It is particularly promising for skin problems caused by diabetes mellitus, and its preclinical results were reported in the Journal of Investigative Dermatology in 2009 and 2011.Remedor Biomed is currently preparing for phase 1 and phase 2 clinical trials.